37results about How to "Clear activity" patented technology

The invention belongs to the technical field of prevention and treatment of pulmonary fibrosis, and relates to an application of cucuribitane tetracyclic triterpenoids in resisting the pulmonary fibrosis. The invention provides the application of the cucuribitane tetracyclic triterpenoids in preparing medicines and / or health-care products for preventing and / or treating pulmonary fibrosis diseases. According to the invention, the novel pharmaceutical application of the cucuribitane tetracyclic triterpenoids, namely the application of the cucuribitane tetracyclic triterpenoids in preparing the medicines and / or health-care products for preventing and / or treating the pulmonary fibrosis diseases, is provided.

The invention discloses a Chinese cordyceps sinensis protein polysaccharide and preparation and application thereof. The Chinese cordyceps sinensis protein polysaccharide is composed of polysaccharide with 55%-60% weight percentage and protein with 40%-45% weight percentage; and the ingredients of the polysaccharide are mannose, ribose, glucose, galactose, xylose and arabinose; the ratio of amount of substances among the mannose, the ribose, the glucose, the galactose, the xylose and the arabinose is 6.42-6.51: 2.20-2.32: 65.85-65.95: 2.10-2.18: 4.20-4.30. The Chinese cordyceps sinensis protein polysaccharide preparation method comprises the following steps: extracting the Chinese cordyceps sinensis protein polysaccharide by aqueous extract and alcohol precipitation, removing the protein, dialyzing, exchanging chromatography by anion and purifying gel filter layer chromatography through an enzyme-Sevage combination method, and freezing, drying and separating purification components in vacuum, and the Chinese cordyceps sinensis protein polysaccharide is acquired. According to the preparation and the application thereof, proximate analysis, structural identification and immunologic function study are carried out on the components of polysaccharide after purification, and the facts that the Chinese cordyceps sinensis protein polysaccharide has strong immunoregulation activity and is a potential immunological enhancement substance are discovered.

The invention belongs to the technical field of medicine, discloses the application of andrographolide derivatives in the preparation of medicines for preventing and treating fibrosis of various tissues and organs of human body, and relates to the structure-modified derivatives of andrographolide decahydronaphthalene. It has the structure of general formula II. Experiments have proved that this type of compound significantly inhibits the migration and activation of hepatic stellate cells LX‑2; significantly inhibits TGF‑β1-induced mesenchymal transition (EMT) of human alveolar type II-like cells A549 and kidney epithelial cells HK‑2. Significantly inhibited the migration of primary human cardiac fibroblasts HCFB induced by angiotensin Ⅱ (Ang Ⅱ). Using this type of compound as an active ingredient to prepare anti-fibrosis drugs of human tissues and organs has high efficiency and low toxicity, and provides a new drug approach for the treatment and prevention of diseases related to fibrosis, thereby expanding the optional range of clinical medication, and has the advantages of Good prospects for application development.

Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.

The invention belongs to the technical field of medicine and relates to 15-methylene-14-deoxy-11,12-dehydro-andrographolide derivatives. It has been proved by experiments that this type of compound significantly inhibits the migration and activation of hepatic stellate cells; significantly inhibits TGF‑β1-induced mesenchymal transition of human alveolar type II epithelial cells A549; significantly inhibits human renal cortical proximal tubule epithelial cells HK‑2 mesenchymal transition; significantly inhibits angiotensin Ⅱ (AngⅡ)-induced migration of primary human cardiac fibroblasts HCFB. Using this type of compound as an active ingredient to prepare anti-fibrosis drugs has high efficiency and low toxicity, and provides a new drug approach for the treatment and prevention of fibrosis-related diseases, thereby expanding the optional range of clinical drugs and having good application development prospect.

The invention discloses a pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds. The structural formula of the polycyclic fused macrocyclic lactam compounds is shown in the description; and in the formula, R1 is OCH3 or H, R2 is Cl or OH, and R3 is OCH3 or H. The polycyclic fused macrocyclic lactam compounds are separated through separating and purifying a fermentation liquid of Streptomyces xiamenensis CGMCC No.4.3534 from mangrove soil. Prepared ikarugamycin and derivatives thereof can inhibit proliferation and vitality of human pancreas cancer cells, and can be used to prepare pancreas cancer prevention drugs.

The invention relates to an application of total dendrobium crepidatum alkaloids in preparing a medicament for treating acute and chronic inflammation, acute and chronic arthritis or rheumatoid arthritis diseases, and the content of the total dendrobium crepidatum alkaloids is 80-91 percent; and shown through a great amount of experiments by an inventor, the total dendrobium crepidatum alkaloids have a good effect on inflammation treatment. The total dendrobium crepidatum alkaloids have better stability and good anti-inflammation activity, and can be used for preparing medicaments for treating corresponding diseases. The total dendrobium crepidatum alkaloids have clear activity, and the experimental materials come from plants, so that the cost is low.

The invention relates to a pharmaceutical composition for treating diabetes and its application, belonging to the technical field of medicine. The technical problem solved by the present invention is to provide a pharmaceutical composition for treating diabetes. The pharmaceutical composition for treating diabetes of the present invention, the active ingredient is composed of the following components by weight: 1-18 parts of pentagalloyl glucose, 1-12 parts of geniposide. The present invention combines PGG and geniposide in the prevention and treatment of diabetes and its complications, combines the advantages of both in hypoglycemic, anti-inflammatory, anti-oxidation, protection of islet cells, and alleviation of insulin resistance, and provides a new way for clinical treatment of diabetes. Drugs for its complications provide a more comprehensive and effective option. The experimental materials involved in the invention come from original plants, the original plants have a wide range, low cost, clear activity of the extract, less toxic and side effects, and wide practical value.

The invention discloses a single / dual-atom catalyst and a controllable synthesis method and application thereof. Firstly, porous carbon nanosheets are prepared. Through simple synthesis conditions, precise control of atomic-level structure is realized, and active centers and active sites are more clearly defined. It is conducive to a deeper understanding of the catalytic mechanism, and at the same time, it is applied to electrocatalytic carbon dioxide reduction, showing excellent catalytic activity, good catalytic stability, low preparation cost, and strong practical applicability, which can be used in The field of electrocatalytic carbon dioxide reduction has excellent application prospects.

The invention relates to a compound with effects of resisting inflammation and platelet activation and aggregation as well as a preparation method and application thereof. The compound has the structure of (25R)-26-oxy-beta-D-glucopyranose-5alpha-furostanol-3beta,12beta,22,26-tetraalcohol-3-oxy-beta-D-glucopyranose(1->2)[beta-D-glucopyranose(1->3)]-beta-D-glucopyranose(1->4)-beta-D-galapyranoside. The effects of the compound in the field of cardial vessels are comprehensively researched from platelet aggregation, platelet activation, platelet calcium ion variation, platelet activation signal transduction pathway and expression of platelet activation relevant inflammatory factors in the invention for the first time. Results show that the compound is a substance found to be with a strong effect on resisting platelet aggregation so far in the allium macrostemon saponin compounds, which has the stronger effect than that of aspirin with the same concentration; and the compound simultaneously has an obvious effect on resisting relevant platelet inflammations. The compound provided by the invention can be applied to medicines for treating thrombus and atherosclerosis.